ClinicalTrials.gg
CompletedNCT00788710Updated Feb 9, 2022Results posted

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

A Phase 3 interventional study of etoricoxib (MK0663) 120 mg and Comparator: Placebo in Acute Pain Following a Total Abdominal Hysterectomy, sponsored by Organon and Co. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.

02

Conditions studied

  • Acute Pain Following a Total Abdominal Hysterectomy

Browse trials for

03

In context

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

This study's enrollment of 430 is above the median of 86 across 903 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption

Exclusion criteria

Exclusion Criteria:

  • Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has to aspirin or other NSAIDS
  • Patient has uncontrolled high blood pressure
  • Patient has a history of drug and/or alcohol abuse within the last 5 years
  • Patient has taken part in another study within 4 weeks of the start of study
  • Patient is breast-feeding
  • Patient has an active ulcer or inflammatory bowel disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
430 participants (actual)

Study arms

  • Experimental
    Etoricoxib 120 mg

    etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.

    Drug: etoricoxib (MK0663) 120 mg

  • Experimental
    Etoricoxib 90 mg

    etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.

    Drug: etoricoxib (MK0663) 90 mg

  • Placebo comparator
    Placebo

    Placebo- 3 tablets once daily

    Drug: Comparator: Placebo

Interventions

  • 120 mg of etoricoxib (MK0663) for a total of 5 days

    Also known as: Arcoxia

  • DrugComparator: Placebo

    Placebo tablets once daily on Days 1-5. Total treatment is 5 days.

  • 90 mg of etoricoxib (MK0663) for a total of 5 days

06

What researchers measure

Primary outcomes

  1. Average Pain Intensity at Rest Over Days 1 to 3

    Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

    Time frame: 3 Days

Secondary outcomes

  1. Average Total Daily Dose of Morphine Over Days 1 to 3

    Time frame: 3 days

  2. Average Elicited Pain Upon Sitting Over Days 1 to 3

    Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

    Time frame: 3 days

07

Results

Posted Jul 22, 2011
Limitations and caveats
11 participants were screened \& 10 participants were randomized at site 0028. An audit showed study medication dispensing logs were not kept. These 10 participants were invalidated and excluded from both efficacy \& safety analyses.

Participant flow

Participant flow — Overall Study
MilestoneEtoricoxib 120 mgEtoricoxib 90 mgPlacebo
Started144142144
Completed139134138
Not completed586
Withdrew: Adverse event134
Withdrew: Lack of efficacy001
Withdrew: Lost to follow-up010
Withdrew: Physician decision210
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject220

Outcome measures

PrimaryAverage Pain Intensity at Rest Over Days 1 to 3

Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

Time frame:
3 Days
Reported as:
Least squares mean · Score on a scale
Average Pain Intensity at Rest Over Days 1 to 3
Score on a scaleEtoricoxib 120 mgEtoricoxib 90 mgPlacebo
Average Pain Intensity at Rest Over Days 1 to 32.40 ± 0.152.46 ± 0.153.26 ± 0.15
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · ANOVA · p = <0.001
  • Etoricoxib 90 mg vs Placebo · ANOVA · p = <0.001
SecondaryAverage Total Daily Dose of Morphine Over Days 1 to 3
Time frame:
3 days
Reported as:
Least squares mean · milligrams (mg)
Average Total Daily Dose of Morphine Over Days 1 to 3
milligrams (mg)Etoricoxib 120 mgEtoricoxib 90 mgPlacebo
Average Total Daily Dose of Morphine Over Days 1 to 35.37 ± 0.085.46 ± 0.087.75 ± 0.08
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · ANOVA · p = <0.001
  • Etoricoxib 90 mg vs Placebo · ANOVA · p = <0.001
SecondaryAverage Elicited Pain Upon Sitting Over Days 1 to 3

Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

Time frame:
3 days
Reported as:
Least squares mean · Score on a scale
Average Elicited Pain Upon Sitting Over Days 1 to 3
Score on a scaleEtoricoxib 120 mgEtoricoxib 90 mgPlacebo
Average Elicited Pain Upon Sitting Over Days 1 to 33.58 ± 0.173.80 ± 0.174.71 ± 0.17
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · ANOVA · p = <0.001
  • Etoricoxib 90 mg vs Placebo · ANOVA · p = <0.001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib 120 mg—5/144 (3.5%)60/144 (41.7%)
Etoricoxib 90 mg—5/142 (3.5%)51/142 (35.9%)
Placebo—10/144 (6.9%)65/144 (45.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventEtoricoxib 120 mgEtoricoxib 90 mgPlacebo
FaecalomaGastrointestinal disorders0/1441/1420/144
Operative haemorrhageInjury, poisoning and procedural complications0/1441/1420/144
HypokalaemiaMetabolism and nutrition disorders0/1441/1420/144
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1441/1420/144
Vaginal haemorrhageReproductive system and breast disorders0/1441/1420/144
Respiratory depressionRespiratory, thoracic and mediastinal disorders0/1441/1420/144
Abdominal painGastrointestinal disorders1/1440/1420/144
Small intestinal obstructionGastrointestinal disorders1/1440/1420/144
CellulitisInfections and infestations0/1440/1421/144
Postoperative wound infectionInfections and infestations0/1440/1421/144
Most frequent other events
Most frequent other events
EventEtoricoxib 120 mgEtoricoxib 90 mgPlacebo
NauseaGastrointestinal disorders40/14431/14238/144
PyrexiaGeneral disorders7/1444/14224/144
ConstipationGastrointestinal disorders16/14412/14218/144
FlatulenceGastrointestinal disorders7/14414/14212/144
DizzinessNervous system disorders12/1449/14214/144
HeadacheNervous system disorders9/1448/14214/144
PruritusSkin and subcutaneous tissue disorders5/14413/1426/144
VomitingGastrointestinal disorders10/1447/14210/144

Baseline characteristics

Age, Continuous
Age, Continuous(years)Etoricoxib 120 mgEtoricoxib 90 mgPlaceboTotal
Mean46.3 ± 6.947.0 ± 7.245.7 ± 7.046.3 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib 120 mgEtoricoxib 90 mgPlaceboTotal
Female144142144430
Male0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin. 2012 Aug;28(8):1323-35. doi: 10.1185/03007995.2012.707121. Epub 2012 Jul 16. PubMed 22738802 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2008
First posted
Nov 11, 2008
Start
Oct 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Jul 22, 2011
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00788710
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 11, 2008
Start date
Oct 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Jul 22, 2011
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion